Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
National Eye Institute (NEI)
Phase 1/Phase 2
Central serous chorioretinopathy (CSC) is a retinal disorder characterized by an accumulation
of serous fluid under the retina. Although acute CSC tends to spontaneously resolve on its
own with minimal sequelae, chronic CSC tends to persist and lead to irreversible visual loss.
The pathogenesis of CSC is complex; however, systemic androgens have been implicated.
Finasteride is an anti-androgen medication that is widely used in the treatment of various
conditions. The objective of this study was to investigate the safety and potential efficacy
of oral finasteride as a treatment for chronic CSC.
Five participants with chronic CSC were enrolled into this uncontrolled, unmasked, Phase I/II
study. An oral dose of finasteride, 5 mg daily, was administered to all participants for
Following this, finasteride was withheld and participants were observed for another three
months. If a participant experienced a beneficial effect during the period in which he
received finasteride and then experienced a relapse during the observation period,
finasteride was re-instituted for the remaining period of the study. Relapse was defined as a
return to the baseline maximum lesion height and/or return to baseline lesion volume.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The purpose of this study is to test how the body absorbs and processes new forms of oral
testosterone. Information gained during the study may help develop better forms of
testosterone therapy in the future.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.